Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer
ConclusionsPS 1 –2 and PFI < 3 months were significant predictors of poor response to following treatment for PRROC. Risks and benefits of treatment should be frankly discussed with patients who have these characteristics.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Fallopian Tube Cancer | Japan Health | Ovarian Cancer | Ovaries | Peritoneal Cancer | Study